IDE275 (GSK959) development is progressing into First-in-Human Phase 1 clinical trial(s) for the treatment of MSI-High solid tumors, representing IDEAYA's 5 th potential first-in-class clinical program MSI-High prevalence in endometrial, colorectal, and gastric cancers is ~31%, 20%, and 19%, respectively, highlighting the market potential of IDE275 (GSK959) IDEAYA to receive a $7 million payment for IND acceptance, and potential future aggregate milestones of up to $950 million . IDEAYA has a 50/50 US Profit Share and an 80/20 (GSK/IDEAYA) global research and development cost share SOUTH SAN FRANCISCO, Calif. , Oct.
28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA ), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S.
Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE275 (GSK959), a potential first-in-class and best-in-class Werner Helicase (WRN) inhibitor. IDE275 (GSK959) has demonstrated robust and selective synthetic lethality preclinically in the high microsatellite instability (MSI-High) biomarker setting, and the Phase 1 clinical trial will enroll patients having tumors characterized by MSI-High. "IDE275 represents IDEAYA's fifth potential first-in-class clinical program in our precision medicine oncology pipeline and has a potentially differentiated best-in-class profi.